Cross-Sector entity

MiNK Therapeutics

Company INKT
5

Of the tracked stories, 2 of 2 also mention C-Further, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention MiNK Therapeutics, all published on March 15, 2026.

2 verified stories tracked

Last mentioned: Mar 15, 2026

Entity pulse

Recent coverage · MiNK Therapeutics

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about MiNK Therapeutics

Of the tracked stories, 2 of 2 also mention C-Further, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention MiNK Therapeutics, all published on March 15, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering MiNK Therapeutics. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Release

    Expected date for Q4 and full-year 2025 financial results and clinical updates.

  2. MiNK Collaboration

    MiNK Therapeutics announces partnership with C-Further for pediatric cancer therapies, stock rises 60%.

Stories mentioning MiNK Therapeutics 2

Biotech pharma Neutral 5

Coya and MiNK Set for Key Earnings: Focus on Treg and iNKT Pipeline Milestones

Coya Therapeutics and MiNK Therapeutics are scheduled to report quarterly financial results this Tuesday, with investors focused on cash runway and clinical progress. These updates come at a critical juncture for both companies as they advance novel cell therapies for neurodegeneration and oncology, respectively.

2 sources
Healthcare market trends Neutral 5

Biotech Earnings Preview: Coya and MiNK Therapeutics Set for Tuesday Reports

Coya Therapeutics and MiNK Therapeutics are scheduled to release quarterly financial results this Tuesday, providing critical updates on their clinical pipelines and cash runways. Investors are closely monitoring MiNK's recent pediatric cancer collaboration and Coya's progress in neurodegenerative Treg therapies.

2 sources

Source: themarketsdaily.com · themarketsdaily.com